Moxonidine

Drug #936

Moxonidine is antihypertensive agent acts on imidazoline sub-type 1 receptors to the brain medula. Used alone or in combination therapy to reduce mild to moderate blood pressure. May cause dry mouth, headache, nausea and insomnia.

← Previous drug Next drug →

Primary Characteristics

It belongs to Methylpyrimidine.

It belongs to Alpha-2 adrenergic agonist pharmacological group on the basis of mechanism of action and also classified in Antihypertensive Agents pharmacological group.

Molecular Weight: 241.7 · Solubility in Water: very slightly soluble · Solubility in Alcohol: Sparangly soluble · Non-proprietary name: Moxonidine.

Pharmacokinetics

Absorption: Moxonidine has an oral bioavailability is 88%.

Distribution: Moxonidine has a plasma protein binding is 7 %.

Elimination: plasma half-life is 2-3hr.

Indications

Moxonidine is primarily indicated in conditions like Hypertension, Mild iron-deficiency anaemias.

Contraindications

Moxonidine is contraindicated in conditions like Depression, Glucoma, Parkinsonism, Raynaud's phenomenon.

Dosage

Moxonidine's dosage details are as follows:

Dose	Single Dose	Frequency	Instructions
Adult Dosage
200 ug	200 ug	Every 24h	Initially.
400 ug	400 ug	—	As a single or in 2 divided doses .
600 ug	600 ug	—	After further 3 weeks
Paediatric Dosage (20kg)
0 – 0	—	—	Not recommended for this age group
Neonatal Dosage (3kg)
0 – 0	—	—	Not recommended in this age group

Drug Interactions

4 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

The signs and symptoms that are produced after acute overdosage of Moxonidine are Bradycardia, Coma, Miosis, Sedation , Transient hypertension.

Moxonidine is known to cause more or less tolerable side effects which are usually transient. These include Anorexia , Burning, Constipation , Dizziness, Dry mouth, Headache, Itching, Sleep disturbancesX, Tiredness .

Warnings / Precautions

Moxonidine should not be given to patients with conduction disorder, bradycardia, severe arrhythmias, severe heart failure, severe ischaemic heart disease, severe liver or kidney impairment or history of angioedema. It should not be stopped abruptly but should be withdrawn gradually over 2 weeks.

Available Brands

None recorded.

Storage Conditions

Moxonidine should be stored .

Drug Classification

1.12.3.6 — Centrally acting sympathoplegic drugs